• „PERFECT FIT“: Orion Pharma signs sales collaboration for DeltaScan® in Germany

    „PERFECT FIT“: Sales collaboration between Orion Pharma and Prolira for early detection and monitoring for acute encephalopathy and delirium.
    The companies ORION Pharma and Prolira are excited to announce their sales collaboration agreement that has been signed in June 2021. The agreement includes the Germany-wide promotion of DeltaScan®, a revolutionary medical device that objectively monitors the brain state of patients. Within minutes, the patient’s brain is assessed for signs of illness (acute encephalopathy and delirium). Monitoring the brain state of hospitalized patients is as important as monitoring other vital organs like the heart or the lungs. Until now this was difficult, as usual care only has subjective checklists with limited performance.

    With DeltaScan®, the brain state is objectively measured at the bedside using breakthrough EEG technology. DeltaScan® is a CE marked device, and is already in use in hospitals in the Netherlands, Germany and Austria in the field of intensive care medicine, geriatric traumatology, cardio thoracic surgery and emergency medicine.

    ORION Pharma is a proven, very well networked specialist in the field of intensive care medicine with a long history of expertise in delirium management, prevention and care. With the successful launches of dexdor® (dexmedetomidine) and SIMDAX® (levosimendan) , ORION Pharma has high professional competence and profound knowledge in intensive care and is a long-established and reliable partner for cardiologists, cardiac surgeons, anaesthetists and intensive care physicians, nurses and pharmacists in clinics in Europe. “The collaboration with Prolira secures our commitment as leading critical care specialist, improving outcomes in intensive care, post cardiac surgery and geriatric trauma patients significantly”, says Dr. Robert Borgdorf, Head of ORION Pharma Region Central Europe. “It has always been our goal to develop solution concepts in collaboration with our customers that really help critical ill patients. With DeltaScan we will continue this path in delirium management”, adds Dr. Markus Gutschow, Business Manager critical care.

    Prolira, a spin-off of the University Medical Center Utrecht (NL), an international and privately owned MedTech Scale Up company, has developed DeltaScan®. “Our objective is to further build our position as the first and only bedside EEG for medical decision making in brain state monitoring. The brain is our central organ and it provides an essential vital sign about the condition of the patient. Every year, as many as 10 million cases of acute brain failure occur in the US and Europe. Hence, there is a large group of patients that are in need of early detection and monitoring of acute encephalopathy and delirium”, says Rutger van Merkerk, MSc. PhD and CEO/Founder of Prolira. “We expect from this ’perfect fit’-collaboration with ORION Pharma a more rapid and increased use of DeltaScan® to improve outcome of this high-risk patient group”; confirms Sjoerd Kruijff, Chief Sales & Marketing of Prolira.

    DeltaScan® is an EU registered trademark (Certificate Nr 018280613) Version 2.0

    Postal Address (for every letter/parcel/package):
    Prolira BV, Kruytgebouw, UInc
    Winthontlaan 30C
    3526 KV Utrecht
    The Netherlands

    Visiting Address:
    Prolira BV, Kruytgebouw
    Padualaan 8
    3584 CH Utrecht


    +31 (0)85 060 1656